| Application no. and date | 03025535.0 (espacenet) (Federated) (European Patent Register), 19991202 | | Patent/reg. no. and date | DK/EP 1386917, 20110622 | | Publication date | 20040204 | | Priority no. and date | SE 9804211, 19981204, SE 9901271, 19990409 | | EP pub. no. and date |
EP 1386917 20040204 | | Effective date | | | Applicant/owner | AstraZeneca AB,
151 85 Södertälje, SE | | Applicant ref. no. | AST A2049-3XEP | | Inventor | Hardern, David, 6 Charnwood Fields
Loughborough
LE12 5NP, GB,
Ingall, Anthony, Astrazeneca R&D Charnwood
Bakewell Road
Loughborough
Leics.
LE11 5RH, GB,
Springthorpe, Brian, AstraZeneca R&D Charnwood
Bakewell Road
Loughborough
Leics. LE11 5RH, GB,
Willis, Paul, Astrazeneca R&D Charnwood
Bakewell Road
Loughborough
Leics.
LE11 5RH, GB,
Guile, Simon, Astrazeneca R&D Charnwood
Bakewell Road
Loughborough
Leics.
LE11 5RH, GB | | Representative | | | Opponent | | | IPC Class | C07D 239/48 (2006.01) | | Title | Mellemprodukter til fremstilling af visse triazolopyrimidiner som P2T antagonister | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
